Nabriva Therapeutics AG (NBRV) Given Buy Rating at HC Wainwright
Nabriva Therapeutics AG (NASDAQ:NBRV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research upgraded Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research report on Friday, August 12th. Leerink Swann reissued an “outperform” rating and set a $14.00 price objective on shares of Nabriva Therapeutics AG in a research note on Thursday, October 27th. Finally, Wedbush reissued an “outperform” rating and set a $17.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus target price of $13.85.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded up 6.25% during trading on Friday, reaching $4.25. The company’s stock had a trading volume of 16,327 shares. The stock’s 50-day moving average is $5.91 and its 200-day moving average is $7.30. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $10.69. The stock’s market cap is $90.30 million.
Large investors have recently modified their holdings of the company. Jackson Park Capital LLC purchased a new stake in shares of Nabriva Therapeutics AG during the second quarter valued at about $195,000. Opaleye Management Inc. raised its stake in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares during the period. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Nabriva Therapeutics AG during the third quarter valued at about $2,468,000. 63.05% of the stock is owned by hedge funds and other institutional investors.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.